Equities

Guerbet SA

Guerbet SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)35.60
  • Today's Change-0.75 / -2.06%
  • Shares traded30.68k
  • 1 Year change+74.51%
  • Beta0.7078
Data delayed at least 15 minutes, as of Sep 20 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

  • Revenue in EUR (TTM)785.69m
  • Net income in EUR23.87m
  • Incorporated1968
  • Employees2.92k
  • Location
    Guerbet SA15 rue des Vanesses, Zone Paris Nord IIVILLEPINTE 93420FranceFRA
  • Phone+33 145915000
  • Fax+33 145915199
  • Websitehttps://www.guerbet.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tristel Plc47.13m7.20m225.60m213.0031.606.0522.094.790.12560.12560.82190.65670.9921.516.26185,394.4015.178.8617.1010.2482.5980.6315.2910.633.93411.730.1605109.9915.7010.14351.986.409.8818.05
Nyxoah SA4.79m-43.54m261.83m147.00--2.18--54.64-1.49-1.490.16423.500.0330.57592.1632,643.05-29.96-23.73-33.61-25.9862.4862.42-908.49-1,469.595.16--0.0959--40.99---38.39--100.58--
BICO Group AB198.33m-69.28m268.11m828.00--1.05--1.35-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Detection Technology Oyj-100.00bn-100.00bn270.40m464.00--3.66----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
Medistim ASA46.02m8.92m282.13m152.0031.588.6025.496.135.705.7029.4120.931.170.73196.343,542,250.0022.7122.9327.5928.5279.4978.2519.3820.642.40--0.026275.257.0010.06-8.9112.720.03314.87
COLTENE Holding AG251.64m13.01m299.10m1.19k23.042.8414.781.192.062.0639.8916.731.271.386.06198,668.906.5510.4811.7018.7464.9062.685.177.470.861910.180.342179.94-9.133.54-54.05-6.81-7.72-7.79
IVF Hartmann Holding AG161.12m18.59m359.12m298.0019.322.4114.552.237.357.3563.7258.840.87883.148.52502,947.4010.147.2912.068.9055.2153.2911.548.303.95--0.005852.16-1.792.0934.951.49-14.8326.82
Synektik SA144.90m18.61m361.57m164.0019.439.0117.412.509.329.3272.5420.092.0316.347.224,043,567.0026.0410.2441.6515.7926.6522.8612.858.851.2813.970.090947.00167.81--409.18------
RaySearch Laboratories AB (publ)99.38m13.32m383.12m403.0037.067.2910.363.864.414.4132.9122.410.57014.503.112,901,244.007.641.2911.801.8890.4890.5713.402.551.17--0.393769.0021.1610.26243.060.7648-1.31--
Ion Beam Applications SA465.75m7.85m409.42m1.84k50.294.3720.880.8790.26890.268915.993.090.77212.152.70234,517.101.301.556.014.3234.1935.231.692.380.63723.770.399264.8318.6710.74-250.40---8.06--
medmix AG505.49m-1.90m412.20m2.70k--0.8396.790.8154-0.05-0.0511.3511.300.47783.405.58180,474.00-0.09962.06-0.12272.4932.5836.38-0.20854.161.062.210.436167.701.991.40-97.41-64.3612.01--
Guerbet SA785.69m23.87m450.02m2.92k19.791.195.400.57281.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Stratec SE255.98m14.58m517.32m1.46k35.492.2715.422.021.201.2021.0618.710.58411.365.23168,187.303.337.074.228.2027.0827.325.699.700.94014.720.397640.81-4.636.88-55.293.30-2.16-7.68
Surgical Science Sweden AB73.81m17.41m547.25m265.0031.441.3524.347.413.873.8716.4390.020.16951.497.353,224,027.004.004.494.264.7868.5170.0623.5923.753.46--0.000.0010.0168.1424.47--38.57--
Advanced Medical Solutions Group plc156.47m13.29m584.53m1.50k44.112.0221.813.740.0510.0510.60111.120.39771.704.91154,244.703.386.543.647.0654.4556.758.4914.826.80--0.270225.851.514.23-22.14-6.7115.6612.32
CellaVision AB63.96m12.77m590.16m221.0046.209.0735.949.236.086.0830.4531.000.7831.766.663,185,965.0015.6415.3018.1818.2466.6269.0319.9719.981.99103.580.0574110.185.9413.1710.128.0030.458.45
Data as of Sep 20 2024. Currency figures normalised to Guerbet SA's reporting currency: Euro EUR

Institutional shareholders

12.63%Per cent of shares held by top holders
HolderShares% Held
Healthinvest Partners ABas of 31 Dec 2023410.00k3.24%
Amundi Asset Management SA (Investment Management)as of 31 Jul 2024183.62k1.45%
Quaero Capital SAas of 31 Dec 2023180.90k1.43%
BNP Paribas Asset Management Europe SASas of 30 Aug 2024150.13k1.19%
HC Capital Advisors GmbHas of 30 Jun 2024131.36k1.04%
Dimensional Fund Advisors LPas of 05 Sep 2024128.59k1.02%
Oddo BHF Asset Management SASas of 30 Aug 2024125.03k0.99%
Generali Asset Management SGR SpAas of 30 Dec 2022111.95k0.89%
Apo Asset Management GmbHas of 30 Sep 202388.00k0.70%
Amplegest SASas of 31 Aug 202387.34k0.69%
More ▼
Data from 29 Feb 2024 - 18 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.